South Korea Metastatic Lung Adenocarcinoma Treatment Market Size & Outlook
The metastatic lung adenocarcinoma treatment market in South Korea is expected to reach a projected revenue of US$ 141.7 million by 2030. A compound annual growth rate of 12.6% is expected of South Korea metastatic lung adenocarcinoma treatment market from 2025 to 2030.
Revenue, 2024 (US$M)
$69.5
Forecast, 2030 (US$M)
$141.7
CAGR, 2025 - 2030
12.6%
Report Coverage
South Korea
South Korea metastatic lung adenocarcinoma treatment market, 2018-2030 (US$M)
Related Markets
South Korea metastatic lung adenocarcinoma treatment market highlights
- The South Korea metastatic lung adenocarcinoma treatment market generated a revenue of USD 69.5 million in 2024 and is expected to reach USD 141.7 million by 2030.
- The South Korea market is expected to grow at a CAGR of 12.6% from 2025 to 2030.
- In terms of segment, chemotherapy was the largest revenue generating treatment in 2024.
- Immunotherapy is the most lucrative treatment segment registering the fastest growth during the forecast period.
Metastatic lung adenocarcinoma treatment market data book summary
| Market revenue in 2024 | USD 69.5 million |
| Market revenue in 2030 | USD 141.7 million |
| Growth rate | 12.6% (CAGR from 2025 to 2030) |
| Largest segment | Chemotherapy |
| Fastest growing segment | Immunotherapy |
| Historical data | 2018 - 2023 |
| Base year | 2024 |
| Forecast period | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Other |
| Key market players worldwide | Pfizer Inc, Eli Lilly and Co, AstraZeneca PLC, Bristol-Myers Squibb Co, Boehringer Ingelheim, Novartis AG ADR, Merck KGaA, Roche Holding AG, GlaxoSmithKline, AbbVie Inc |
Other key industry trends
- In terms of revenue, South Korea accounted for 1.4% of the global metastatic lung adenocarcinoma treatment market in 2024.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, China metastatic lung adenocarcinoma treatment market is projected to lead the regional market in terms of revenue in 2030.
- South Korea is the fastest growing regional market in Asia Pacific and is projected to reach USD 141.7 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Metastatic Lung adenocarcinoma Treatment Market Scope
Metastatic lung adenocarcinoma treatment market segmentation & scope
Metastatic Lung adenocarcinoma Treatment Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
South Korea metastatic lung adenocarcinoma treatment market size, by treatment, 2018-2030 (US$M)
South Korea Metastatic Lung adenocarcinoma Treatment Market Outlook Share, 2024 & 2030 (US$M)
Related industry reports
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
